Overall impact
B (65)

Commentary

Alkermes is a strong overall performer. With a 'B' rating of 65.4 for overall impact (74th percentile compared to all companies), Alkermes ranks 90th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 86 others, and ahead of Evolus, Oyster Point Pharma, Jiangsu Hengrui Medicine and 61 others. On top material causes for Alkermes's industry (Pharmaceuticals & Biotech), Alkermes performs well in Child and Maternal Health (93.8 score), Child and Maternal Health (95.0), Access to Affordable Healthcare (96.0) and 2 other causes where it received an 'A' score and performs poorly in Accountable Institutions (18.4 score), Humane Treatment of Animals (0.0), Reduced Inequality (39.4) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause ALKS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1987
Employees
2,050
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ireland
Share classes
ALKS
Mission
Science with a Purpose. Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.
Description
Alkermes plc is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, as well as a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc., and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Material causes
Ethos considers the following causes material for Alkermes, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.